HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

References

• Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expert Rev Clin Immunol. 2008;4:13–10. doi:10.1586/1744666X.4.1.13.
   PubMed Web of Science ®Google Scholar
• Gower RG, Busse PJ, Aygören-Pürsün E, Barakat AJ, Caballero T, Davis-Lorton M, Farkas H, Hurewitz DS, Jacobs JS, Johnston DT, et al. Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J. 2011;4:S9–s21. doi:10.1186/1939-4551-4-S2-S9.
   PubMedGoogle Scholar
• Schmaier AH, Emsley J, Feener EP, Gailani D, Govers-Riemslag JWP, Kaplan AP, Maas C, Morrissey JH, Renné T, Sidelmann JJ, et al. Nomenclature of factor XI and the contact system. J Thromb Haemost. 2019;17:2216–19. doi:10.1111/jth.14595.
   PubMed Web of Science ®Google Scholar
• de Maat S, Maas C. Factor XII: form determines function. J Thromb Haemost. 2016;14:1498–506. doi:10.1111/jth.13383.
   PubMed Web of Science ®Google Scholar
• Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood. 2012;120:4296–303. doi:10.1182/blood-2012-07-292094.
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–97. doi:10.1016/S0140-6736(97)09137-X.
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104:1321–22. doi:10.1016/S0091-6749(99)70030-8.
   PubMed Web of Science ®Google Scholar
• Cao H, Biondo M, Lioe H, Busfield S, Rayzman V, Nieswandt B, Bork K, Harrison LC, Auyeung P, Farkas H, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018;142:1355–58. doi:10.1016/j.jaci.2018.06.014.
   PubMed Web of Science ®Google Scholar
• Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6:222ra217. doi:10.1126/scitranslmed.3006804.
   Web of Science ®Google Scholar
• Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399:945–55. doi:10.1016/S0140-6736(21)02225-X.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/record/NCT04739059. Long-term safety and efficacy of CSL312 (Garadacimab) in the prophylactic treatment of hereditary angioedema attacks (clinicalTrials.gov identifier: NCT04739059). U.S. National Library of Medicine, Last accessed: 10 May 2022.
   Google Scholar
• Pawaskar D, Chen X, Glassman F, May F, Roberts A, Biondo M, McKenzie A, Nolte MW, Jusko WJ, Tortorici M. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). Clin Transl Sci. 2022;15:709–20. doi:10.1111/cts.13192.
   PubMed Web of Science ®Google Scholar
• Engen JR, Komives EA. Complementarity of hydrogen/deuterium exchange mass spectrometry and cryo-electron microscopy. Trends Biochem Sci. 2020;45:906–18. doi:10.1016/j.tibs.2020.05.005.
   PubMed Web of Science ®Google Scholar
• Englander SW. Hydrogen exchange and mass spectrometry: a historical perspective. J Am Soc Mass Spectrom. 2006;17:1481–89. doi:10.1016/j.jasms.2006.06.006.
   PubMed Web of Science ®Google Scholar
• Masson GR, Jenkins ML, Burke JE. An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. Expert Opin Drug Discov. 2017;12:981–94. doi:10.1080/17460441.2017.1363734.
   PubMed Web of Science ®Google Scholar
• Puchades C, Kűkrer B, Diefenbach O, Sneekes-Vriese E, Juraszek J, Koudstaal W, Apetri A. Epitope mapping of diverse influenza Hemagglutinin drug candidates using HDX-MS. Sci Rep. 2019;9:4735. doi:10.1038/s41598-019-41179-0.
   PubMed Web of Science ®Google Scholar
• Wales TE, Eggertson MJ, Engen JR. Considerations in the analysis of hydrogen exchange mass spectrometry data. Methods Mol Biol. 2013;1007:263–88.
   PubMedGoogle Scholar
• Chalmers MJ, Busby SA, Pascal BD, He Y, Hendrickson CL, Marshall AG, Griffin PR. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2006;78:1005–14. doi:10.1021/ac051294f.
   PubMed Web of Science ®Google Scholar
• Hamuro Y. Determination of equine cytochrome c backbone amide hydrogen/deuterium exchange rates by mass spectrometry using a wider time window and isotope envelope. J Am Soc Mass Spectrom. 2017;28:486–97. doi:10.1007/s13361-016-1571-1.
   PubMed Web of Science ®Google Scholar
• Hamuro Y, Coales SJ. Optimization of feasibility stage for hydrogen/deuterium exchange mass spectrometry. J Am Soc Mass Spectrom. 2018;29:623–29. doi:10.1007/s13361-017-1860-3.
   PubMed Web of Science ®Google Scholar
• Cummins DJ, Espada A, Novick SJ, Molina-Martin M, Stites RE, Espinosa JF, Broughton H, Goswami D, Pascal BD, Dodge JA, et al. Two-site evaluation of the repeatability and precision of an automated dual-column hydrogen/deuterium exchange mass spectrometry platform. Anal Chem. 2016;88:6607–14. doi:10.1021/acs.analchem.6b01650.
   PubMed Web of Science ®Google Scholar
• Espada A, Haro R, Castañon J, Sayago C, Perez-Cozar F, Cano L, Redero P, Molina-Martin M, Broughton H, Stites RE, et al. A decoupled automation platform for hydrogen/deuterium exchange mass spectrometry experiments. J Am Soc Mass Spectrom. 2019;30:2580–83. doi:10.1007/s13361-019-02331-2.
   PubMed Web of Science ®Google Scholar
• Watson MJ, Harkewicz R, Hodge EA, Vorauer C, Palmer J, Lee KK, Guttman M. Simple platform for automating decoupled LC-MS analysis of hydrogen/deuterium exchange samples. J Am Soc Mass Spectrom. 2021;32:597–600. doi:10.1021/jasms.0c00341.
   PubMed Web of Science ®Google Scholar
• Dementiev A, Silva A, Yee C, Li Z, Flavin MT, Sham H, Partridge JR. Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors. Blood Adv. 2018;2:549–58. doi:10.1182/bloodadvances.2018016337.
   PubMed Web of Science ®Google Scholar
• Pathak M, Wilmann P, Awford J, Li C, Hamad BK, Fischer PM, Dreveny I, Dekker LV, Emsley J. Coagulation factor XII protease domain crystal structure. J Thromb Haemost. 2015;13:580–91. doi:10.1111/jth.12849.
   PubMed Web of Science ®Google Scholar
• Ständer SR, Grauslund L, Scarselli M, Norais N, Rand K. Epitope mapping of polyclonal antibodies by hydrogen–deuterium exchange mass spectrometry (HDX-MS). Anal Chem. 2021;93:11669–78. doi:10.1021/acs.analchem.1c00696.
   PubMed Web of Science ®Google Scholar
• Willard L, Ranjan A, Zhang H, Monzavi H, Boyko RF, Sykes BD, Wishart DS. VADAR: a web server for quantitative evaluation of protein structure quality. Nucleic Acids Res. 2003;31:3316–19. doi:10.1093/nar/gkg565.
   PubMed Web of Science ®Google Scholar
• Davies AM, Sutton BJ. Human IgG4: a structural perspective. Immunol Rev. 2015;268:139–59. doi:10.1111/imr.12349.
   PubMed Web of Science ®Google Scholar
• Handlogten MW, Peng L, Christian EA, Xu W, Lin S, Venkat R, Dall’Acqua W, Ahuja S. Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region. MAbs. 2020;12:1779974. doi:10.1080/19420862.2020.1779974.
   PubMed Web of Science ®Google Scholar
• Panousis C, Rayzman V, Nash A, Wilson M, Schmidbauer S, Nolte M. Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses (Patent Number: EP2548892A1). European Patent Office: CSL Behring GmbH, 2011.
   Google Scholar
• Worm M, Köhler EC, Panda R, Long A, Butler LM, Stavrou EX, Nickel KF, Fuchs TA, Renné T. The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities. Ann Transl Med. 2015;3:247–247. doi:10.3978/j.2305-5839.2015.09.07.
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Ferrara F, Naranjo L, Erasmus MF, Hraber P, Bradbury ARM. Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.00395.
   Web of Science ®Google Scholar
• Peng HP, Lee KH, Jian JW, Yang AS. Origins of specificity and affinity in antibody-protein interactions. Proc Natl Acad Sci U S A. 2014;111:E2656–2665. doi:10.1073/pnas.1401131111.
   PubMed Web of Science ®Google Scholar
• Keskin O. Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies. BMC Struct Biol. 2007;7:31. doi:10.1186/1472-6807-7-31.
   PubMed Web of Science ®Google Scholar
• Al Qaraghuli MM, Kubiak-Ossowska K, Ferro VA, Mulheran PA. Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response. Sci Rep. 2020;10:13696. doi:10.1038/s41598-020-70680-0.
   PubMed Web of Science ®Google Scholar
• Sela-Culang I, Alon S, Ofran Y. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol. 2012;189:4890–99. doi:10.4049/jimmunol.1201493.
   PubMed Web of Science ®Google Scholar
• Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, et al. Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proc Natl Acad Sci U S A. 2015;112:13898–903. doi:10.1073/pnas.1515558112.
   PubMed Web of Science ®Google Scholar
• Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290–96. doi:10.1038/nmeth.4169.
   PubMed Web of Science ®Google Scholar
• Perspicace S, Banner D, Benz J, Müller F, Schlatter D, Huber W. Fragment-based screening using surface plasmon resonance technology. J Biomol Screen. 2009;14:337–49. doi:10.1177/1087057109332595.
   PubMed Web of Science ®Google Scholar
• Masson GR, Burke JE, Ahn NG, Anand GS, Borchers C, Brier S, Bou-Assaf GM, Engen JR, Englander SW, Faber J, et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Nat Methods. 2019;16:595–602. doi:10.1038/s41592-019-0459-y.
   PubMed Web of Science ®Google Scholar
• Walters BT, Ricciuti A, Mayne L, Englander SW. Minimizing back exchange in the hydrogen exchange-mass spectrometry experiment. J Am Soc Mass Spectrom. 2012;23:2132–39. doi:10.1007/s13361-012-0476-x.
   PubMed Web of Science ®Google Scholar
• Bern M, Kil YJ, Becker C. Byonic: advanced peptide and protein identification software. Curr Protoc Bioinformatics. 2012;40: Chapter 13:Unit13.20. doi:10.1002/0471250953.bi1320s40.
   Google Scholar
• Hamuro Y, Coales SJ, Southern MR, Nemeth-Cawley JF, Stranz DD, Griffin PR. Rapid analysis of protein structure and dynamics by hydrogen/deuterium exchange mass spectrometry. J Biomol Tech. 2003;14:171–82.
   PubMedGoogle Scholar